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Neonatal invasive disease caused by group B Streptococcus (GBS) represents a
significant public health care concern globally. However, data related to disease burden,
serotype distribution, and molecular epidemiology in China and other Asian countries
are very few and specifically relative to confined regions. The aim of this study was to
investigate the genetic characteristics of GBS isolates recovered from neonates with
invasive disease during 2013–2014 at Guangzhou and Changsha hospitals in southern
mainland China. We assessed the capsular polysaccharide type, pilus islands (PIs)
distribution and hvgA gene presence in a panel of 26 neonatal clinical isolates, of which
8 were recovered from Early Onset Disease and 18 from Late Onset Disease (LOD).
Among 26 isolates examined, five serotypes were identified. Type III was the most
represented (15 cases), particularly among LOD strains (n = 11), followed by types
Ib (n = 5), V (n = 3), Ia (n = 2) and II (n = 1). We performed whole-genome sequencing
analysis and antimicrobial susceptibility testing on the 14 serotype III isolates belonging
to the hypervirulent Clonal Complex 17 (serotype III-CC17).The presence of PI-2b alone
was associated with 13 out of 14 serotype III-CC17 strains. Genome analysis led us
to identify two multi-drug resistance gene clusters harbored in two new versions of
integrative and conjugative elements (ICEs), carrying five or eight antibiotic resistance
genes, respectively. These ICEs replaced the 16 kb-locus that normally contains the
PI-1 operon. All isolates harboring the identified ICEs showed multiple resistances to
aminoglycoside, macrolide, and tetracycline antibiotic classes. In conclusion, we report
the first whole-genome sequence analysis of 14 GBS serotype III-CC17 strains isolated
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in China, representing the most prevalent lineage causing neonatal invasive disease.
The acquisition of newly identified ICEs conferring multiple antibiotic resistance could
in part explain the spread of this specific clone among Chinese neonatal isolates and
underlines the need for a constant epidemiological surveillance.
Keywords: Streptococcus agalactiae, whole-genome sequencing (WGS), pilus island (PI), integrative conjugative
element (ICE), antimicrobial resistance, resistome, clonal complex (CC), sequence type (ST)
INTRODUCTION
In the 1970s Streptococcus agalactiae (group B Streptococcus,
GBS) emerged as predominant pathogen causing sepsis and
meningitis in neonates and infants younger than 3 months in
the United States and other Western countries (Baker, 2013).
GBS can also cause invasive disease in adult patients with
underlying medical conditions (Skoff et al., 2009). Asymptomatic
GBS colonization of the genital and gastrointestinal tracts of
up to 30% of healthy women is the primary risk factor for
Early Onset Disease (EOD) occurring in newborns within the
6 days of life (Heath and Schuchat, 2007). The neonate is usually
infected by exposure to GBS during delivery, and bacteria can
rapidly spread into the bloodstream with rapid appearance of
clinical signs like pneumonia, sepsis, or meningitis (Simonsen
et al., 2014). Infections occurring in infants between 7 and
89 days of age are designated Late Onset Disease (LOD) and are
characterized by meningitis in up to 50% of cases (Joubrel et al.,
2015). The introduction of national guidelines recommending
universal screening of pregnant women for GBS carriage and
use of intrapartum antibiotic prophylaxis during delivery has
significantly reduced the incidence of EOD (Puopolo et al., 2005;
Melin, 2011). However, these guidelines have no effect on LOD
incidence and their implementation is not feasible in most low
and middle-income countries (Dagnew et al., 2012; Johri et al.,
2013). Alternative strategies, such as maternal immunization are
under evaluation (Melin and Efstratiou, 2013; Nuccitelli et al.,
2015; Donders et al., 2016).
The capsular polysaccharide (CPS) that GBS expresses into
10 antigenically unique types (Ia, Ib, and II–IX) represents
a major virulence factor and vaccine target for its ability
to induce protective immunity (Edwards, 2008). Additionally,
several surface proteins such as the components of filamentous
pilus polymers extending outside the bacterial surface have been
identified as important virulence factors and promising vaccine
candidates (Maione et al., 2005; Johri et al., 2006). In GBS, three
pilus variants (type 1, 2a, and 2b) were described, and all strains
carry at least one variant (Margarit et al., 2009).
GBS disease in all age groups is mainly caused by five
capsular types (Ia, Ib, II, III, and V) and the serotype III
accounts for about 50% of neonatal disease globally (Edmond
et al., 2012; Le Doare and Heath, 2013). In particular, type
III isolates belonging to the sequence type (ST) 17 lineage
account for about 60% of LOD meningitis cases, compared
to less than 10% of colonizing isolates (Manning et al., 2009;
Joubrel et al., 2015). Due to its epidemiological relevance, the
type III/ST-17 has been defined as hypervirulent and its high
invasiveness is presumably associated to additional virulence
factors besides the CPS (Jones et al., 2006). Genome-based studies
described this clone as a homogeneous cluster of strains of recent
origin displaying a conserved specific pattern of genes encoding
secreted and surface proteins, including the pilus 1 and pilus
2b operons and the Gbs2018C/hvgA gene (Brochet et al., 2006;
Springman et al., 2014). The Gbs2018C/hvgA gene codes for a
ST-17 specific surface-anchored protein called hypervirulent GBS
adhesin (HvgA) and can be used to specifically identify GBS
ST-17 strains (Lamy et al., 2006; Tazi et al., 2010). Functional
characterization of this protein has shown that its expression
in vivo is associated with GBS hypervirulence, as HvgA was
required for intestinal colonization and translocation across the
intestinal and the blood–brain barrier, and the onset of meningitis
(Tazi et al., 2010).
While the burden of GBS disease in infants has been widely
investigated in Western countries, only few studies have been
carried out so far in Eastern countries, including China (Dagnew
et al., 2012; Johri et al., 2013; Wang et al., 2015a). A GBS
invasive disease rate of 0.28 per 1000 live births was estimated
in a prospective study conducted in Southern mainland China,
and four serotypes (Ia, Ib, III, and V) were associated with
the identified cases (Liu et al., 2015). A recent analysis of
GBS neonatal isolates recovered from 2008 to 2013 in Beijing
and Shenzhen reported similar serotype distribution, with a
clear prevalence of type III/CC17 strains (Wang et al., 2015a).
Particularly high rates of antibiotic resistance have been detected
among isolates circulating in China both in infected neonates
(Wang et al., 2015a) and in carrier women (Lu et al., 2014; Wang
et al., 2015b).
Here, we investigated the genetic characteristics of 26 GBS
isolates recovered at Guangzhou and Changsha hospitals from
neonates with invasive disease during 2013–2014, and selected
14 serotype III strains belonging to the CC17 for further whole
genome sequencing (WGS) analysis, with particular attention to
their antibiotic resistome.
MATERIALS AND METHODS
Bacterial Strains, Media, and Growth
Conditions
The strain collection analyzed in this study included 26
GBS clinical isolates recovered in China during 2013–2014
from neonates with invasive disease, mostly in Guangzhou
hospital and one isolate in Changsha. Eight strains were
prospectively isolated from cases enrolled during a former
observational study (Liu et al., 2015) while 16 isolates were
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retrospectively collected in the same region. GBS COH1,
a clinical isolate obtained from an infected newborn with
sepsis at the Children’s Orthopedic Hospital (COH; Wilson
and Weaver, 1985) was used as reference serotype III-ST17
strain in all performed assays. All GBS isolates used in this
study and their relative information are listed in Table 1.
A GBS case was identified when an infant younger than
3 months was GBS-culture positive from a sterile site (blood or
cerebral spinal fluid), with any of the signs of clinical disease
(e.g., sepsis, pneumonia, or meningitis). The presence of GBS
in samples was determined within routine internal hospital
laboratory services using the BD BACTECTM 9210 Culture
System and API 20STREP (Guangzhou) and BD BACTECTM
9120 Blood Culture System and CAMP test (Changsha). GBS
isolates were collected and stored in STGG stock medium
at –70◦C.
S. agalactiae strains were grown at 37◦C in 5% CO2 in Todd
Hewitt Broth (Difco Laboratories), in trypticase soy-agar or
Muller-Hinton-agar supplemented with 5% sheep blood.
The study protocols were approved by the Novartis Vaccines
Research Institutional Board and by the Medical Ethical
Committees of Guangzhou Women and Children’s Medical
Center and of Changsha Hospital for Maternal and Child Health.
The study was conducted in accordance with guidelines for
Good Pharmacoepidemiology Practices and the Declaration of
Helsinki. Informed consent was obtained from all subjects.
Strain Serotyping by Latex Agglutination
Serotyping was performed using the standard Strep-B-Latex
rapid agglutination method (Strep-B-Latex kit; Statens Serum
Institut, Denmark). A heavy suspension of the test organism was
prepared by harvesting bacteria from the agar plate in 250 µl of
phosphate-buffered saline (PBS, pH 7.4). A 20 µl aliquot of the
bacterial suspension was mixed with 5 µl of each of the ten Latex
reagents (rabbit antisera Ia, Ib, and II–IX) onto a disposable card.
The reaction card was rotated slowly and a positive reaction was
indicated by agglutination appearing within 30 s.
Antimicrobial Susceptibility Test
The E test strips (Biomiereux) method was used to assess the
antimicrobial susceptibility by determining the minimal
inhibitory concentrations (MICs) of these antibiotics:
azithromycin, benzylpenicillin, clindamycin, erythromycin,
levofloxacin, ceftriaxone, claritromycin, tetracycline,
vancomycin. The breakpoints adopted were in accordance with
the 2015 criteria set by the European committee on antimicrobial
susceptibility testing based on tables for interpretation of MICs
TABLE 1 | Streptococcus agalactiae isolates used in this study.
Isolate name Isolation source Onset of disease Isolation country Reference NCBI BioProject ID/Accession number
CH-1 CSF LOD Guangzhou Liu et al., 2015 PRJNA324749
CH-2 blood LOD Guangzhou Liu et al., 2015 PRJNA324749
CH-3 blood EOD Changsha Liu et al., 2015
CH-4 CSF LOD Guangzhou Liu et al., 2015
CH-5 blood LOD Guangzhou Liu et al., 2015
CH-6 blood EOD Guangzhou Liu et al., 2015
CH-7 CSF LOD Guangzhou Liu et al., 2015
CH-8 blood LOD Guangzhou Liu et al., 2015
GZ01 Blood EOD Guangzhou This study PRJNA324749
GZ02 Blood EOD Guangzhou This study PRJNA324749
GZ04 CSF LOD Guangzhou This study
GZ05 Blood EOD Guangzhou This study PRJNA324749
GZ06 Blood LOD Guangzhou This study PRJNA324749
GZ07 Blood EOD Guangzhou This study
GZ08 Blood EOD Guangzhou This study PRJNA324749
GZ09 Blood EOD Guangzhou This study
GZ11 Blood LOD Guangzhou This study PRJNA324749
GZ12 Blood LOD Guangzhou This study PRJNA324749
GZ13 Blood LOD Guangzhou This study PRJNA324749
GZ14 CSF LOD Guangzhou This study PRJNA324749
GZ15 Uri LOD Guangzhou This study
GZ16 Blood LOD Guangzhou This study
GZ18 Blood LOD Guangzhou This study
GZ19 Blood LOD Guangzhou This study PRJNA324749
GZ20 CSF LOD Guangzhou This study PRJNA324749
CS01 Blood LOD Changsha This study PRJNA324749
COH1 Blood USA Wilson and Weaver, 1985 HG939456
CSF, cerebrospinal fluid; EOD, early-onset disease (0 to <7 days); LOD, late-onset disease (7–90 days); Uri, urine.
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version 5.01. The susceptibility for kanamycin, gentamycin,
streptomycin, lincomycin, and spectinomycin was defined by
Société Française de Microbiologie2.
Genomic DNA Preparation
Genomic DNA was prepared from overnight GBS cultures
by a standard protocol for Gram-Positive bacteria, using
Mutanolysin-treatment of bacterial cells and a Gene Elute
Bacterial Genomic DNA kit (Sigma–Aldrich) according to the
manufacturer’s instructions.
Molecular Analysis by PCR-Based
Assays
A molecular capsular genotyping was used to confirm the
Latex serotype assignment and to identify the capsular type
of GBS isolates resulting serologically non-typeable (NT). The
assay was performed by multiplex PCRs using a previously
published method (Poyart et al., 2007) modified in house
by including a new primer pairs specific for serotype IX
detection (5′-AGATCATTTGTTCCTGATTCCCTAAAG-3′; 5′-
AATCATCTTCATAATTTATCTCCCATT-3′). The pattern for
type IX strains detected two amplicons (371 and 1,132 base pairs).
The protocol is based on two multiplex PCRs, one containing the
primer pairs specific for serotypes Ia, Ib, II, III, and IV and the
other containing the primer pairs specific for serotypes V, VI, VII,
VIII, and IX.
Pilus genes were PCR-amplified using primers specifically
annealed to conserved genomic regions external to the coding
sequences as already described (Margarit et al., 2009).
The presence of the Gbs2018/hvgA gene was assessed as
previously described (Lamy et al., 2006; Tazi et al., 2010).
Whole Genome Sequencing (WGS),
Genome Assembly, and Annotation
Whole-genome sequencing was performed on libraries
generated using 1 ng of purified bacterial DNA processed
by Nextera XT DNA Library Preparation Kit (Illumina).
Samples were normalized with a bead-based approach,
pooled in an equal amount and finally diluted for the deep
sequencing run, following Nextera XT protocol. Sequencing
was carried out on a HiSeq 2500 platform in a 100 bp
paired-end run with the TruSeq SBS version 3 chemistry
(Illumina).
The newly sequenced genomes were assembled using SPAdes
3.0.0 (Bankevich et al., 2012). The contigs number ranged
between 38 and 54, with an average of 45. All obtained draft
genome assemblies were annotated with Prokka (Seemann,
2014) using a genus specific non-redundant BLAST database,
built from all the translated annotations retrieved from RefSeq
(Pruitt et al., 2009) for TaxId 1311, clustered with CD-HIT
(Fu et al., 2012). The newly sequenced genomes were deposited
in the NCBI database under the BioProject ID PRJNA324749.
1http://www.eucast.org
2http://www.sfm-microbiologie.org
Genome Alignments and Sequence
Analysis
The complete genome of GBS COH1 (Accession number
HG939456) was used as reference sequence for genome analysis.
Genome comparison and visualization was performed by BRIG
software (Alikhan et al., 2011).
Sequence types were assigned by comparing the genomic
sequences with the seven housekeeping genes of the GBS MLST
(Multi Locus Sequence Type) system (Jones et al., 2003)3 using
the Bio-MLST-Check-2.0.1510612 suite4. Clonal Complexes
(CCs) were assigned as previously reported (Rosini et al., 2015).
ICEs sequence alignments and comparison were performed using
Easyfig (Sullivan et al., 2011). ICE sequence similarities were
searched on the ICEberg server (Bi et al., 2012). ICESag(RR1)
from CH-2 isolate was used as reference sequence for reads
mapping and subsequent sequence comparison of the ICEs
from all GBS genomes. Reads mapping and multiple alignments
were performed using Geneious R9 with default settings5. The
distribution of the antibiotic resistance genes present in the
Antibiotic Resistance Database (Liu and Pop, 2009) and the
RESFAMS database (Gibson et al., 2015) within the genomes of
the 14 newly sequenced isolates was investigated using custom
scripts based on the BLAST and HMMer algorithms.
RESULTS
Most Analyzed GBS Isolates Are
Associated to ST-17 and Carry Only Pilus
Island 2b
To investigate the genetic characteristics of a clinically
relevant GBS population from Southern China, we
3http://pubmlst.org/sagalactiae/
4http://search.cpan.org/~{}ajpage/Bio-MLST-Check-2.0.1510612/
5http://www.geneious.com
TABLE 2 | Characteristics of the 26 GBS neonatal invasive isolates
recovered in China.
Capsular polysaccharide (CPS) type
Ia Ib II III V Total
Disease
EOD 1 2 4 1 8
LOD 1 3 1 11 2 18
Pilus Islands
PI-2a 2 2 4
PI-2b 13 13
PI-1+2a 3 1 1 3 8
PI-1+2b 1 1
hvgA
hvgA– 2 5 1 1 3 12
hvgA+ 14 14
Data are number of isolates. EOD, early onset disease; LOD, late onset disease; PI,
pilus island; hvgA (Gbs2018C), hypervirulent GBS adhesion gene.
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collected 26 isolates from infants affected by sepsis and
meningitis in Guangzhou/Changsha area. Eight strains
were obtained from EOD cases and 18 from neonates with
LOD.
We first assessed the CPS type and the pilus islands (PIs)
distribution by serological and PCR-based assays. Serotype III
was the most prevalent accounting for 58% of all isolates (15/26)
among both EOD (4/8) and LOD (11/18), followed by type Ib
(19%; 5/26), type V (11%; 3/26), and type Ia (8%; 2/26). One
genotype II strain was NT by serological analysis (4%; 1/26)
(Table 2).
To verify whether the prevalent serotype III was associated
to the hypervirulent ST-17 lineage as in previous observations
related to the same region (Wang et al., 2015a), the isolates were
screened for the presence of the hvgA gene, a characteristic feature
of the ST-17 strains (Lamy et al., 2006). PCR results showed that
14 strains, all CPS type III, were hvgA positive and thus ST-17-
associated. Only one type III isolate was negative for the presence
of the gene and, as expected, the same was true for all strains
belonging to other serotypes.
Concerning PIs distribution, half of the analyzed isolates only
harbored PI-2b in their genomes (13 out of 26 strains). Moreover,
FIGURE 1 | Multi whole-genome comparison. (A) The complete group B Streptococcus (GBS) COH1 (HG939456) genome was used as reference and
compared against the 14 sequenced and assembled genomes. The innermost ring shows the COH1 genome length (kbp). The remaining rings show BLAST
comparison of the 14 sequenced genomes: CH-1, GZ02, GZ05, GZ08, GZ11, GZ14, CS01, GZ06, CH-2, GZ12, GZ19, GZ20, and GZ113 from ring 2 to 15. Full
colors represent a sequence identity over 99%. Interruptions in a colored ring indicate areas of the COH1 reference chromosome that are missing in the represented
genomes (Locus 1, 2, and 3). (B) Schematic representation of GBS COH1 Locus 1 comprising pilus island genes (blue), Locus 2 including the tn916 element
carrying tetM gene (red), and the integrase gene int (green). A phage-related region is present in Locus 3.
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all these isolates presenting the PI-2b-alone genotype belonged
to CPS type III-ST-17. The PI-1+2a combination was present in
eight strains distributed among four CPS types (three for type Ib
and V each, one for type II and III). Finally, PI-2a alone was found
in the four strains belonging to CPS types Ia or Ib (Table 2).
In conclusion, the vast majority of type III strains (14/15)
belonged to the ST-17 lineage, and all but one carried the PI-
2b alone, an uncommon genotype among type III-ST-17 isolates
characterized so far (Springman et al., 2014).
Whole Genome Sequencing Analysis
Confirmed that Type III Chinese Isolates
Belong to CC17
To further investigate the molecular characteristics of the 14
identified hvgA-positive serotype III strains we performed WGS.
In silico MLST analysis and CC assignment of the newly
sequenced genomes confirmed that all strains belonged to CC17,
and specifically 12 were strictly ST-17 while two had novel
ST profiles that were single locus variants (s.l.v.) of ST-17.
Further sequence analysis confirmed both the presence of the
type III cps operon and the PI-2b in all strains and the absence
of the otherwise well-conserved PI-1 in 13 of these 14 CC17
strains. To assess DNA sequence similarity, we performed BLAST
pairwise sequence comparisons between each genome and the
complete chromosome of the ST-17 reference strain COH1.
Figure 1 provides a comprehensive view of all single comparisons
by displaying similarity between the central COH1 reference
sequence and the other draft genomes as concentric rings. All
analyzed genomes shared more than 99% sequence identity to
the reference genome across at least 94% of its whole length.
We also identified three distinct genomic loci in the COH1
reference chromosome (locus 1, 2, and 3) that could not be
found in some of the newly sequenced strains. These regions
are indicated by interruptions in the circular map that represent
each genome (Figure 1A). Locus 1 is absent in all analyzed
genomes except for one, while locus 2 and locus 3 are absent
in 9 and 7 genomes, respectively. According to the curated
annotation of the COH1 genome, locus 1 includes the entire pilus
island 1 plus 15 genes belonging to different functional categories
(Supplementary Table 1). Locus 2 and 3 mainly contain predicted
open reading frames belonging to mobile elements along with
poorly characterized hypothetical genes. Particularly, locus 2
includes a well-known large integrative conjugative element
(ICE) Tn916 carrying the tetM gene conferring resistance to
tetracycline (Da Cunha et al., 2014), while locus 3 hosts a
putative prophage carrying different genes of unknown function
(Figure 1B).
CPS Type III CC17 Chinese isolates Have
Acquired Multi-Drug Resistance Gene
Clusters
Horizontal gene transfer events determining exchange of
large genome tracts are commonly considered an important
mechanism in the diversification of S. agalactiae (Brochet et al.,
2008). Therefore, we hypothesized that the loss in 13 out of
14 sequenced isolates of the genomic region corresponding to
FIGURE 2 | Schematic representation of the newly identified integrative and conjugative elements (ICEs) in GBS genomes. (A) Structural comparison of
ICESag (RR1) with the corresponding regions present in ICESsu (SC84) from Streptococcus suis. Coding sequences (CDSs) of the newly identified ICESag(RR1) in
GBS CH-2 isolate are depicted by arrows. Antibiotic resistance determinants are colored in red, conjugative type IV elements in yellow and integrase function in
green. Blue bands indicate BLAST matches between sequences in the same orientation and orange twisted bands indicate BLAST matches between sequences in
opposite orientations. In both cases, the intensity of the colors indicates the strength of the match. (B) Sequence comparison of the newly identified ICEs by multiple
alignment. Blue lines depict single ICE sequences. Upper green bar represents the resulting sequence identity (green 100% identity, yellow <100% identity).
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FIGURE 3 | Distribution of antibiotic resistance genes and phenotypes in the 14 GBS isolates selected for whole genome sequencing (WGS). Heatmap
representing the copy number of antibiotic resistance genes present in each genome. The antimicrobial susceptibility was assessed by E test determining the
minimal inhibitory concentrations (MICs) to streptomycin (Sm), spectinomycin (Sc), kanamycin (Km), azithromycin (Az), claritromycin (Ch), erythromycin (Em),
clindamycin (Cm), tetracycline (Tc), lincomycin (Lm), levofloxacin (Le), gentamycin (Gm), benzylpenicillin (Pg), ceftriaxone (Tx), vancomycin (Va). R, antibiotic resistant.
All strains were susceptible to penicillin, ceftriaxone, vancomycin, levofloxacin, and gentamycin. COH1 was used as reference genome in the in silico resistome
analysis and as reference strain in the antimicrobial susceptibility tests.
locus 1 could be counterbalanced by the acquisition of new
genetic material, giving a potential selective advantage to these
pathogenic strains. To test this hypothesis, the sequenced draft
genomes were analyzed to look for new genes absent in the
reference strain. The assembly of the sequenced short reads
permitted to partially rebuild the regions corresponding to locus
1 for all 13 strains. We identified a large putative integrative
and conjugative element (ICE), ICESag(RR1) in the PI-1 minus
genomes replacing the entire locus 1. For one genome, namely
CH-2, we were able to isolate the full-length ICE since it was
harbored in a single sequence contig. This mobile element
presented a typical mosaic organization, composed by different
modules that showed a high sequence similarity to other ICEs
found in different other streptococcal species such as S. suis,
S. dysgalactiae, S. pyogenes, S. pneumoniae. Among all the ICEs
present in the ICEberg database (Bi et al., 2012), the newly
identified ICESag(RR1) displayed the highest sequence similarity
(91% identity in a 5772 bp region) to S. suis ICESsu(SC84). More
detailed sequence analysis revealed that the central module of
this large mobile element contained several ORFs annotated as
putative antibiotic resistance genes, including tetO, ermB, ant6,
and aphA, known to confer multiple resistances to tetracycline,
erythromycin and aminoglycosides (Figure 2A). Mapping of the
reads of the remaining 12 strains lacking locus 1 on the extracted
ICE revealed that the sequence identity of this tract was highly
conserved in each strain (>98%) (Figure 2B). Finally, in strains
lacking locus 2 or locus 3 we observed no additional genetic
elements in the corresponding regions.
Identification of a New Genetic Module
Carrying Additional Antibiotic Resistance
Genes
The previous analysis showed that the invasive strains of
our collection could be resistant to multiple antimicrobial
compounds due to the acquisition of an uncommonly large
number of resistance genes hosted on mobile elements. To gain
a clearer picture of the antibiotic resistance gene repertoire of
these strains we performed a deep search of their genomes
using a custom approach integrating different antimicrobial
resistance gene databases. As shown in Figure 3, all sequenced
genomes harbored genes predicted to confer resistance against
aminoglycosides and tetracycline antibiotics. Moreover, with the
exception of GZ13, all sequenced isolates hosted at least one
macrolide resistance gene. In most cases a single copy of each
antibiotic resistance gene was detected, while two or three copies
of ant6 were found in all strains, except for GZ02 that carried a
single copy. Moreover two additional genes predicted to confer
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FIGURE 4 | Sequence comparison of the newly identified ICESag (RR2) and ICE SGB76 from S. agalactiae. An example of composite ICESag (RR2) found
in GBS GZ02, GZ20, GZ06, GZ11, and CS01 isolates. Coding sequences (CDSs) are depicted by arrows. Dotted lines represent the region of insertion of a new
genetic module resembling the GBS ICE SGB76 carrying antibiotic resistance genes (red arrows). Green shadowing indicates 99% of sequence identity. Brown
arrows indicate genes duplicated in ICESag (RR2).
resistance to spectinomycin and lincomycin, ant9 and lnuB, were
identified in a subgroup of strains (GZ02, GZ20, GZ06, GZ11,
and CS01). These genes were contained in a new gene module
similar to the previously described ICE SGB76 (Montilla et al.,
2014), that was found inserted in the ICE Sag(RR1), thus resulting
in a previously undescribed ICE configuration that was named
Sag(RR2) (Figure 4).
Antimicrobial Susceptibility Analysis
Confirmed In silico-Predicted Multi-Drug
Resistance
To verify whether the identified genes were able to confer
antibiotic resistance to the strains harboring them, we tested
susceptibility on plates to 14 different chemical compounds
belonging to different antibiotic classes (benzylpenicillin,
ceftriaxone, streptomycin, spectinomycin, kanamycin,
azithromycin, claritromycin, erythromycin, clindamycin,
lincomycin, tetracycline, levofloxacin, gentamycin, and
vancomycin). The results confirmed that the antibiotic
resistance profiles predicted in silico closely matched the
resistance phenotype observed in vivo (Figure 3). Overall, these
results revealed a direct correlation between the presence of a
specific antibiotic resistance gene and a resistance phenotype.
Compared to COH1 phenotype, 13 CC17 Chinese strains showed
additional antibiotic resistance to macrolides and lincosamides.
Moreover, the subgroup including the strains carrying the
ant9 and lnuB genes showed also resistance to lincomycin
and spectinomycin. Conversely, benzylpenicillin, ceftriaxone,
levofloxacin, gentamycin, and vancomycin proved to be effective
in preventing growth of all isolates.
DISCUSSION
This study reports the first whole-genome sequencing analysis
of GBS clinical isolates collected in China from neonates with
invasive disease. To date, only few surveillance studies on GBS
infections have been carried out in China, and in general,
in Asia, so the burden of disease caused by GBS in infants
younger than 90 days is still unclear. Moreover, data related to
serotype distribution and genetic characteristics of the prevalent
circulating lineages in this particular geographical area are
currently rare, although critical for a deep understanding of the
global epidemiology of GBS infections.
Among the 26 neonatal isolates analyzed in this study, we
found that most were serotype III, and all type III except one
belonged to the well-known hypervirulent CC17 lineage (Musser
et al., 1989). Wang et al. (2015a) recently reported the prevalence
of this specific lineage (CC17-serotype III) among GBS isolates
causing neonatal disease in China, and it is noteworthy that those
isolates also showed resistance to erythromycin, clindamycin,
and tetracycline. Serotype III strains represent the most common
cause of GBS neonatal infections worldwide (Edmond et al.,
2012; Le Doare and Heath, 2013), and the spread of type III
strains, exhibiting increased antibiotic resistance, appears clearly
higher in China than in other countries. Therefore, to investigate
the high prevalence of CC17 strains in this geographic area, we
analyzed by WGS 14 type III-CC17 clinical isolates from infected
neonates collected in the Chinese area. Recent comparative
genomics and phylogenetic analysis have confirmed that isolates
belonging to CC17 have closely similar evolutionary histories
and their observed homogeneity is due to the relatively low
rate of recombination among strains respect to the other CCs
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(Da Cunha et al., 2014; Teatero et al., 2016). Consistently, our
genome analysis has confirmed a high degree of genetic identity
in the GBS CC17 population. Additionally, it has led us to the
identification of multi-drug resistance gene clusters harbored in
at least two different versions of ICEs, carrying five or eight
antibiotic resistance genes, respectively. The acquisition of these
ICEs occurred in a specific genomic locus in 13 out of 14 CC17
isolates analyzed, and balanced the loss of a 16 kb genome region
that include the entire pathogenicity pilus island 1 in the ST-17
reference genome.
Our findings are in agreement and expand recently published
observations by Teatero et al. (2016), who identified 11 CC17
Canadian isolates lacking PI-1 and acquiring in the same
location a mobile genetic element (MGE) encoding resistance
to tetracycline, macrolides and other antibiotics. Until these
discoveries, human-derived CC17 isolates were exclusively
associated with the simultaneous presence of pilus islands 1
and 2b (Springman et al., 2014). Interestingly, a recent study
investigating PI distribution on 160 GBS isolates collected from
colonized pregnant women in six hospital settings in Beijing, 10
out of 14 CC17 isolates contained PI-2b alone (Lu et al., 2015).
Although not confirmed by genome analysis, it is presumable
that also these carrier strains have acquired new genic elements
replacing the PI-1 locus.
These observations lead us to speculate that trading an
important pathogenicity locus for a multi-drug resistance mobile
element could represent one of the causes for the high expansion
of the CC17 lineage among Chinese isolates.
It is known that ICEs are highly variable and could easily
lose or acquire modules (Wozniak and Waldor, 2010). In our
small collection of neonatal isolates, we found a surprisingly
high number of different genes conferring resistance to different
antibiotic classes. These mobile elements are inserted in a specific
genome locus and could acquire additional resistance genes by
recombining their modules. Indeed, it is really interesting to
note that the module containing the ant9 and lnuB genes for
the resistance to lincomycin and spectinomycin was originally
identified in a GBS pathogenic strain isolated in Argentina
(Montilla et al., 2014), a remote location from the region of
isolation of the strains analyzed in this study.
Antimicrobial resistance has been shown to be emerging
worldwide in the GBS population, and in particular, resistance
to clindamycin and erythromycin is increasing (Castor et al.,
2008; CDC, 2012). While none of the 15 analyzed isolates were
resistant to penicillin, vancomycin or ceftriaxone, all of them
were resistant to tetracycline. In addition, all strains harboring
the identified ICEs were resistant to macrolides (claritromycin,
azithromycin, and erythromycin) and kanamycin. Among these,
the subgroup carrying the ant9 and lnuB genes showed also
resistance to spectinomycin and lincomycin. To date, treatment
of GBS infections is mainly based on intra-partum prophylaxis
with penicillin, ampicillin, and cefazolin; second-line drugs such
as vancomycin, macrolides (i.e., erythromycin, azithromycin, and
clarithromycin), and lincosamides (clindamycin and lincomycin)
may be used as alternative in patients allergic to penicillin or
cephalosporins. To date, rare cases of invasive vancomycin-
resistant GBS strains have been isolated from adult patients (Park
et al., 2014). However, the Chinese scenario is of great concern,
since the common usage of human antibiotics in the veterinary
sector in the past decades has led to high incidence of multidrug
resistant bacteria (Cheng et al., 2015). The frequency of resistance
to clindamycin and erythromycin among circulating GBS isolates
in China has been reported to be significantly higher than in other
countries (Wang et al., 2015a,b).
All together these observations underline the importance of
genomic surveillance of epidemiologically relevant lineages and
show the power of the in silico analysis of the GBS resistome to
predict antibiotic resistance phenotypes and to understand the
epidemiology and plasticity of GBS population. Moreover, even
though effective drugs are still available to tackle the majority of
GBS infections, the high plasticity of the MGE carrying multiple
antibiotic resistance genes and the advantage they confer to
pathogens in countries with an extensive antibiotic use, such
as China, underline the need to develop preventive approaches
based on vaccination.
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